Eterna Therapeutics

Update in progress

ERNA (NasdaqCM)

Ernexa Therapeutics Inc. is a preclinical-stage biotech developing induced mesenchymal stem cell (iMSC) therapies for cancer and autoimmune diseases. Its lead products are ERNA-101, an allogeneic iMSC secreting IL-7/IL-15 for ovarian cancer, and ERNA-201, an IL-10–secreting iMSC for rheumatoid arthritis. It has a license with Factor Bioscience. Formerly Eterna Therapeutics, renamed in March 2025. Founded 2018, Cambridge, MA.